Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Be TRI trial of FOLFOXIRI + bevacizumab in untreated metastatic colorectal cancer
jRCTs061180021Completed
- Sponsor
- Yakult Honsha
- Start
- May 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab, irinotecan, oxaliplatin, folinic acid and fluorouracil in colorectal cancer (CRC), sponsored by Yakult Honsha. Primary endpoint: Response rate. Started May 2015; status: completed.
02
Drugs
bevacizumabirinotecanoxaliplatinfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs061180021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180021.